Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain MYOK message board posts where the ticker symbol MYOK has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest MYOK SEC Filings

Filings Format Description Filing Date File/Film Number
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001564590-18-028395 (34 Act)  Size: 12 MB
2018-11-08 001-37609
181169000
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001564590-18-028097 (34 Act)  Size: 289 KB
2018-11-07 001-37609
181167068
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-028348 Size: 18 KB
2018-11-06
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-028347 Size: 6 KB
2018-11-06
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-026330 Size: 16 KB
2018-10-05
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-025124 Size: 11 KB
2018-09-24
8-K  Documents Current report, items 1.01 and 2.03
Acc-no: 0001193125-18-274142 (34 Act)  Size: 26 KB
2018-09-14 001-37609
181071148
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-023935 Size: 14 KB
2018-09-06
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-023934 Size: 14 KB
2018-09-06
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-021742 Size: 14 KB
2018-08-08
More MYOK SEC Filings


Related news from
Mon, 12 Nov 2018
12:30:00 +0000
MyoKardia Presents Preclinical Evidence of Mavacamten’s Novel Effect on Diastolic Compliance at the 2018 American Heart Association Scientific Sessions
MyoKardia is developing mavacamten for the chronic treatment of hypertrophic cardiomyopathy (HCM), a heritable disease caused by the presence of too many cross-bridges formed between the heart muscle proteins myosin and actin. Mavacamten is intended to normalize this excess cross-bridge formation, which underlies the hypercontractility, or elevated force of contraction, and the reduced compliance, or ability of the left ventricle to relax and fill with oxygenated blood, that are both characteristic of HCM.
Thu, 08 Nov 2018
22:34:25 +0000
Eyeing faster path for sickle cell drug, Peninsula biotech plots expansion — for a higher price
One of the first tenants in The Cove at Oyster Point is taking the last building in the South San Francisco development as rents in the region hit new highs.
Thu, 08 Nov 2018
01:50:01 +0000
MyoKardia (MYOK) Reports Q3 Loss, Tops Revenue Estimates
MyoKardia (MYOK) delivered earnings and revenue surprises of 22.00% and 21.45%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Thu, 08 Nov 2018
00:48:49 +0000
MyoKardia: 3Q Earnings Snapshot
The South San Francisco, California-based company said it had a loss of 39 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Wed, 07 Nov 2018
21:38:35 +0000
All this 500,000-square-foot Berkeley biotech project needs is a developer
An eight-acre Berkeley site near Aquatic Park has hit the market, promoted as a potential 475,000-square-foot office project or life science campus. Commercial brokerage firm JLL (NYSE: JLL) is marketing the site at the foot of Addison Street, east of Interstate 80, to potential developers that could take advantage of a biotech building boom in which hundreds of thousands of square feet are being taken quickly, often months before structures are completed.
Wed, 07 Nov 2018
21:30:00 +0000
MyoKardia Reports Third Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of.
Wed, 07 Nov 2018
13:01:00 +0000
MyoKardia to Present at the Credit Suisse 27th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of.
Mon, 05 Nov 2018
13:00:00 +0000
MyoKardia Announces Twelve Abstracts Accepted for Presentation During the 2018 American Heart Association Scientific Sessions
Presentations Include Data from Ongoing Clinical Trials and Preclinical Studies of Mavacamten and HCM Population Insights from the Sarcomeric Human Cardiomyopathy Registry.
Mon, 05 Nov 2018
13:00:00 +0000
MyoKardia to Present Clinical Evidence of Mavacamten’s Effect on Diastolic Function at 2018 American Heart Association Scientific Sessions
Diastolic Relaxation Typically Impaired in HCM Patients; Data Indicate Mavacamten May Improve Ability of the Left Ventricle to Relax and Fill Additional Clinical Evidence of.
Thu, 01 Nov 2018
14:23:59 +0000
Big pharma leases almost 500,000 square feet for new research center
It is one of the largest real estate leases in the Bay Area by traditional drug companies staking out space to establish deeper research and development connections with the region’s hundreds of biotech companies and research universities.
Wed, 31 Oct 2018
14:10:00 +0000
Bears Are Doing an EKG Test on MyoKardia
MYOK is a company that is involved with treating cardiovascular disease. Gianakakos said even though one-third of all people die from some form of cardiovascular disease, there's been little innovation in the space. To get to the cause, you need precision medicine, Gianakakos said, and that's what MyoKardia is doing.
Tue, 30 Oct 2018
11:30:00 +0000
MyoKardia Shares Data from Ongoing Clinical Programs and Details Three New Research Programs at 2018 R&D Day
Interim PIONEER-OLE Data for Mavacamten Demonstrate Reductions in LVOT Obstruction; Ejection Fraction Maintained above Normal Range First-in-Human Data for MYK-491 in Healthy.
Mon, 29 Oct 2018
14:17:02 +0000
Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more
Small VistaGen is building a portfolio of drugs aimed at depression and other mental health conditions, while giant Gilead gets a lower effective tax rate — all that and more in our Health Care Digest.
Thu, 25 Oct 2018
14:34:02 +0000
MyoKardia (MYOK) Q3 Earnings Preview: What's Shaping Up?
MyoKardia (MYOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thu, 25 Oct 2018
04:00:00 +0000
MyoKardia Announces Initiative to Create Hypertrophic Cardiomyopathy Patient Community in Collaboration with 23andMe
MyoKardia, Inc., (MYOK), a clinical stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that it has entered into a collaboration with 23andMe to advance research for patients with hypertrophic cardiomyopathy (HCM), a progressive and frequently debilitating disease characterized by excessive contractility of the heart. MyoKardia is committed to raising awareness and supporting patients and families suffering from this devastating disease, a commitment shared by 23andMe. “We are proud to continue our history of investing in resources for HCM patients and their caregivers, furthering our core value of Patients First.
Wed, 24 Oct 2018
20:30:00 +0000
MyoKardia Doses First Patient in MAVA Long-Term Extension Study of Mavacamten for Hypertrophic Cardiomyopathy
MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that patient dosing has begun in the MAVA Long-Term Extension (MAVA-LTE) clinical trial.
Mon, 22 Oct 2018
12:30:00 +0000
MyoKardia to Host R&D Day on October 30, 2018
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2018 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of.
Fri, 19 Oct 2018
12:30:00 +0000
Recent Analysis Shows Vipshop, MyoKardia, HudBay Minerals, Nordic American Tankers, Yum China, and TIM Participacoes S.A. Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Mon, 24 Sep 2018
12:01:00 +0000
MyoKardia to Present at the 2018 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2018-- MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "I absolutely LOVE ValueForum, and consider this site the most important tool I have for investing and/or trading because of the incredible information at just one site. I have learned so much from reading messages posted here that I recommend to the new comer to select an area of investing that is of interest and then read those posts starting with most current. I am sure you will gain information and learn techniques that can be applied to other areas/sectors of investing. This is an 'Invaluable' forum." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards